BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 9119154)

  • 21. Problems of contamination, exposure, and pollution in freeze-drying biological products.
    LaSalle B
    Dev Biol Stand; 1976 Oct; 36():201-5. PubMed ID: 1030420
    [No Abstract]   [Full Text] [Related]  

  • 22. Experiences of virus, retrovirus and retrovirus-like particles in Chinese hamster ovary (CHO) and hybridoma cells used for production of protein therapeutics.
    Adamson SR
    Dev Biol Stand; 1998; 93():89-96. PubMed ID: 9737383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The road to the biotech revolution: highlights of 100 years of biologics regulation.
    Bren L
    FDA Consum; 2006; 40(1):50-7. PubMed ID: 16528828
    [No Abstract]   [Full Text] [Related]  

  • 24. Issues related to harmonization of testing requirements for viral safety.
    Hayakawa T
    Dev Biol Stand; 1996; 88():15-8. PubMed ID: 9119129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Process changes and their effect on process evaluation for viral clearance.
    Marcus-Sekura C
    Dev Biol Stand; 1996; 88():125-30. PubMed ID: 9119123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adventitious agents from animal-derived raw materials and production systems.
    Hellman KB; Honstead JP; Vincent CK
    Dev Biol Stand; 1996; 88():231-4. PubMed ID: 9119142
    [No Abstract]   [Full Text] [Related]  

  • 27. Licensing of protein products from the milk of transgenic animals. Validation for pathogen removal--a strategy.
    Wright G; Colman A; Cottom D; Williams M
    Dev Biol Stand; 1996; 88():269-76. PubMed ID: 9119150
    [No Abstract]   [Full Text] [Related]  

  • 28. Viral safety evaluation of biopharmaceuticals and homoeopathic preparations of human or animal origin.
    Immelmann A
    Pharmeur Sci Notes; 2006 Aug; 2006(1):41-5. PubMed ID: 17694646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current issues in viral assays and viral clearance evaluation.
    Lubiniecki AS
    Dev Biol Stand; 1996; 88():9-11. PubMed ID: 9119167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Philosophy and goals of validation for biotech products and the relevance of scale.
    Hageman TC
    Dev Biol Stand; 1992; 76():231-7. PubMed ID: 1478341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Membrane filtration for virus removal.
    Brandwein H; Aranha-Creado H
    Dev Biol (Basel); 2000; 102():157-63. PubMed ID: 10794103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel, Q-PCR based approach to measuring endogenous retroviral clearance by capture protein A chromatography.
    Zhang M; Lute S; Norling L; Hong C; Safta A; O'Connor D; Bernstein LJ; Wang H; Blank G; Brorson K; Chen Q
    Biotechnol Bioeng; 2009 Apr; 102(5):1438-47. PubMed ID: 18988264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An overview of quantitative PCR assays for biologicals: quality and safety evaluation.
    Xu Y; Brorson K
    Dev Biol (Basel); 2003; 113():89-98. PubMed ID: 14620857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of removal of human retroviruses.
    Marcus-Sekura CJ
    Dev Biol Stand; 1992; 76():215-23. PubMed ID: 1478339
    [No Abstract]   [Full Text] [Related]  

  • 35. Appropriate mammalian expression systems for biopharmaceuticals.
    Werner RG; Noé W; Kopp K; Schlüter M
    Arzneimittelforschung; 1998 Aug; 48(8):870-80. PubMed ID: 9748718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retrovirus screening of vaccine cell substrates.
    Khan AS
    Dev Biol Stand; 1996; 88():157-62. PubMed ID: 9119131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Introductory remarks: viral safety of biologicals.
    Horaud F
    Dev Biol Stand; 1991; 75():3-7. PubMed ID: 1794630
    [No Abstract]   [Full Text] [Related]  

  • 38. Strategies to avoid virus transmissions by biopharmaceutic products.
    Werz W; Hoffmann H; Haberer K; Walter JK
    Arch Virol Suppl; 1997; 13():245-56. PubMed ID: 9413543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals.
    Farshid M; Taffs RE; Scott D; Asher DM; Brorson K
    Curr Opin Biotechnol; 2005 Oct; 16(5):561-7. PubMed ID: 16095899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-time quantitative PCR for retrovirus-like particle quantification in CHO cell culture.
    de Wit C; Fautz C; Xu Y
    Biologicals; 2000 Sep; 28(3):137-48. PubMed ID: 10964440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.